Literature DB >> 26556996

Colitis-associated colon cancer: Is it in your genes?

Lauren Van Der Kraak1, Philippe Gros1, Nicole Beauchemin1.   

Abstract

Colitis-associated colorectal cancer (CA-CRC) is the cause of death in 10%-15% of inflammatory bowel disease (IBD) patients. CA-CRC results from the accumulation of mutations in intestinal epithelial cells and progresses through a well-characterized inflammation to dysplasia to carcinoma sequence. Quantitative estimates of overall CA-CRC risks are highly variable ranging from 2% to 40% depending on IBD severity, duration and location, with IBD duration being the most significant risk factor associated with CA-CRC development. Recently, studies have identified IBD patients with similar patterns of colonic inflammation, but that differ with respect to CA-CRC development, suggesting a role for additional non-inflammatory risk factors in CA-CRC development. One suggestion is that select IBD patients carry polymorphisms in various low penetrance disease susceptibility genes, which pre-dispose them to CA-CRC development, although these loci have proven difficult to identify in human genome-wide association studies. Mouse models of CA-CRC have provided a viable alternative for the discovery, validation and study of individual genes in CA-CRC pathology. In this review, we summarize the current CA-CRC literature with a strong focus on genetic pre-disposition and highlight an emerging role for mouse models in the search for CA-CRC risk alleles.

Entities:  

Keywords:  Azoxymethane; Colitis-associated colorectal cancer; Dextran sulfate sodium; Forward genetics; Inflammatory bowel disease; Mouse models; Susceptibility genes

Mesh:

Year:  2015        PMID: 26556996      PMCID: PMC4631970          DOI: 10.3748/wjg.v21.i41.11688

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  101 in total

Review 1.  Inflammation and colorectal cancer: colitis-associated neoplasia.

Authors:  Sergei I Grivennikov
Journal:  Semin Immunopathol       Date:  2012-11-16       Impact factor: 9.623

2.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 3.  Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis.

Authors:  Saleh A Naser; Melissa Arce; Anam Khaja; Marlene Fernandez; Najih Naser; Sammer Elwasila; Saisathya Thanigachalam
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

4.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

5.  Heritable susceptibility for colitis in mice induced by IL-10 deficiency.

Authors:  I J Bristol; M A Farmer; Y Cong; X X Zheng; T B Strom; C O Elson; J P Sundberg; E H Leiter
Journal:  Inflamm Bowel Dis       Date:  2000-11       Impact factor: 5.325

6.  Genetic control of susceptibility to carcinogen-induced colorectal cancer in mice: the Ccs3 and Ccs5 loci regulate different aspects of tumorigenesis.

Authors:  Charles Meunier; Tony Kwan; Claire Turbide; Nicole Beauchemin; Philippe Gros
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

7.  Intestinal inflammation targets cancer-inducing activity of the microbiota.

Authors:  Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin
Journal:  Science       Date:  2012-08-16       Impact factor: 47.728

8.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

9.  Five new mouse susceptibility to colon cancer loci, Scc11-Scc15.

Authors:  Claudia A L Ruivenkamp; Tamás Csikós; Anita M Klous; Tom van Wezel; Peter Demant
Journal:  Oncogene       Date:  2003-10-16       Impact factor: 9.867

10.  Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer.

Authors:  Ian P M Tomlinson; Luis G Carvajal-Carmona; Sara E Dobbins; Albert Tenesa; Angela M Jones; Kimberley Howarth; Claire Palles; Peter Broderick; Emma E M Jaeger; Susan Farrington; Annabelle Lewis; James G D Prendergast; Alan M Pittman; Evropi Theodoratou; Bianca Olver; Marion Walker; Steven Penegar; Ella Barclay; Nicola Whiffin; Lynn Martin; Stephane Ballereau; Amy Lloyd; Maggie Gorman; Steven Lubbe; Bryan Howie; Jonathan Marchini; Clara Ruiz-Ponte; Ceres Fernandez-Rozadilla; Antoni Castells; Angel Carracedo; Sergi Castellvi-Bel; David Duggan; David Conti; Jean-Baptiste Cazier; Harry Campbell; Oliver Sieber; Lara Lipton; Peter Gibbs; Nicholas G Martin; Grant W Montgomery; Joanne Young; Paul N Baird; Steven Gallinger; Polly Newcomb; John Hopper; Mark A Jenkins; Lauri A Aaltonen; David J Kerr; Jeremy Cheadle; Paul Pharoah; Graham Casey; Richard S Houlston; Malcolm G Dunlop
Journal:  PLoS Genet       Date:  2011-06-02       Impact factor: 5.917

View more
  16 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

2.  The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.

Authors:  Dakota N Jackson; Kibrom M Alula; Yaritza Delgado-Deida; Redouane Tabti; Kevin Turner; Xuan Wang; K Venuprasad; Rhonda F Souza; Laurent Désaubry; Arianne L Theiss
Journal:  Cancer Res       Date:  2020-07-14       Impact factor: 12.701

Review 3.  Microbiota as a mediator of cancer progression and therapy.

Authors:  Jillian L Pope; Sarah Tomkovich; Ye Yang; Christian Jobin
Journal:  Transl Res       Date:  2016-08-03       Impact factor: 7.012

Review 4.  Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity.

Authors:  Joseph W Dean; Liang Zhou
Journal:  Trends Immunol       Date:  2022-02-05       Impact factor: 16.687

Review 5.  Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.

Authors:  Shailja C Shah; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2021-10-29       Impact factor: 22.682

6.  Molecular Network Analyses Implicate Death-Associated Protein Kinase 3 (DAPK3) as a Key Factor in Colitis-Associated Dysplasia Progression.

Authors:  Huey-Miin Chen; Justin A MacDonald
Journal:  Inflamm Bowel Dis       Date:  2022-10-03       Impact factor: 7.290

7.  PAR2-dependent activation of GSK3β regulates the survival of colon stem/progenitor cells.

Authors:  Imen Nasri; Delphine Bonnet; Bailey Zwarycz; Emilie d'Aldebert; Sokchea Khou; Raoudha Mezghani-Jarraya; Muriel Quaranta; Corinne Rolland; Chrystelle Bonnart; Emmanuel Mas; Audrey Ferrand; Nicolas Cenac; Scott Magness; Laurianne Van Landeghem; Nathalie Vergnolle; Claire Racaud-Sultan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-06-16       Impact factor: 4.052

8.  CAMK2γ in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation.

Authors:  X Ma; Z Meng; L Jin; Z Xiao; X Wang; W M Tsark; L Ding; Y Gu; J Zhang; B Kim; M He; X Gan; J E Shively; H Yu; R Xu; W Huang
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

9.  Chronic Trichuris muris infection causes neoplastic change in the intestine and exacerbates tumour formation in APC min/+ mice.

Authors:  Kelly S Hayes; Laura J Cliffe; Alison J Bancroft; Simon P Forman; Seona Thompson; Cath Booth; Richard K Grencis
Journal:  PLoS Negl Trop Dis       Date:  2017-06-26

Review 10.  The Protective Role of Type I Interferons in the Gastrointestinal Tract.

Authors:  Kevin P Kotredes; Brianna Thomas; Ana M Gamero
Journal:  Front Immunol       Date:  2017-04-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.